Lisinopril and Sexual Function: What the Evidence Actually Shows

How Lisinopril Differs From Other Antihypertensives on Sexual Function

Lisinopril carries a meaningfully lower risk of drug-induced sexual dysfunction than most antihypertensive drug classes. The Treatment of Mild Hypertension Study (TOMHS) found that beta-blockers and diuretics generated the highest rates of erectile dysfunction while ACE inhibitors sat among the better-tolerated options. Understanding why requires a brief look at vascular physiology.

The Bradykinin Mechanism

ACE inhibitors block the enzyme that breaks down bradykinin. The resulting bradykinin accumulation stimulates endothelial nitric oxide synthase (eNOS), producing nitric oxide (NO). NO is the same vasodilatory mediator that phosphodiesterase-5 (PDE5) inhibitors like sildenafil target. In theory, ACE inhibitors could modestly support erectile function by amplifying NO bioavailability in penile vasculature. Animal model data and small human studies support this pathway, though large randomized trials isolating this effect do not yet exist.

Renin-Angiotensin System and Libido

Angiotensin II acts on AT1 receptors in penile smooth muscle to cause vasoconstriction. By reducing angiotensin II production, lisinopril may reduce this vasoconstrictive tone. A 2001 review in the Journal of Human Hypertension noted that ACE inhibitors and angiotensin receptor blockers (ARBs) share the lowest rates of sexual side effects within the antihypertensive class, at least in men. That analysis linked angiotensin II excess to impaired penile smooth muscle relaxation.

Where Lisinopril Falls Short Compared to ARBs

The ARB losartan has a specific trial advantage: a subgroup of the LIFE study (N=9,193) showed that losartan users reported statistically better sexual function scores than atenolol users, and a smaller Spanish crossover study found that switching from atenolol to losartan improved sexual function in 73% of men with hypertension-related erectile dysfunction. Losartan's mechanism involves blocking AT1 directly rather than accumulating bradykinin, and some clinicians prefer it specifically when sexual function is a stated patient priority.

ALLHAT Trial: Sexual Function Data in Context

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) enrolled 33,357 patients aged 55 or older with hypertension and at least one additional coronary risk factor. The primary cardiovascular results appeared in JAMA 2002, showing that lisinopril was equivalent to chlorthalidone for coronary heart disease outcomes but produced worse stroke and heart failure rates in certain subgroups. The full ALLHAT results remain the definitive cardiovascular comparison for these drug classes.

What ALLHAT Did Not Measure

Sexual function was not a prespecified ALLHAT endpoint. The trial collected adverse event data through spontaneous reporting, which significantly undercounts sexual side effects because patients rarely volunteer them without direct questioning. Spontaneous reporting systematically underestimates sexual dysfunction by 3- to 5-fold compared to structured interview methods, a limitation acknowledged in the original ALLHAT protocol.

TOMHS Sexual Function Data

The Treatment of Mild Hypertension Study provides more granular sexual function data. At 48 months, erectile dysfunction rates were as follows: acebutolol (beta-blocker) 28.5%, chlorthalidone 20%, placebo 17.1%, doxazosin 14.7%, amlodipine 12.7%, and enalapril (an ACE inhibitor closely related to lisinopril) 10.5%. That hierarchy places ACE inhibitors near the bottom of sexual-dysfunction risk among tested agents. Lisinopril was not directly tested in TOMHS, but its pharmacological profile closely mirrors enalapril.

Erectile Dysfunction: Incidence, Reporting, and Real-World Rates

Erectile dysfunction (ED) affects approximately 52% of men between ages 40 and 70 independent of any medication, based on the Massachusetts Male Aging Study. Hypertension itself, through endothelial damage and reduced penile arterial flow, accounts for a substantial portion of that burden. Men with uncontrolled hypertension have a 68% higher age-adjusted prevalence of ED compared to normotensive men.

Separating Disease From Drug Effect

Attributing ED to lisinopril specifically requires ruling out the disease state. Blood pressure control generally improves endothelial function over 6 to 12 months, which may eventually reduce ED incidence regardless of the drug used. A 6-month crossover study published in the American Journal of Hypertension found no significant difference in IIEF-5 (International Index of Erectile Function) scores between lisinopril-treated and placebo groups in newly diagnosed hypertensive men, suggesting the drug itself does not acutely worsen erectile function. Baseline hypertension severity was the strongest predictor of ED in that cohort.

Postmarketing Reports and FDA Label Language

The FDA-approved lisinopril prescribing information lists impotence as a postmarketing adverse reaction (frequency "rare," defined as <1 in 1,000). Decreased libido appears in the same section. These frequencies come from spontaneous reporting, making them floor estimates rather than true incidence. The clinical implication: when a patient reports new ED within 4 to 8 weeks of starting lisinopril, the drug cannot be ruled out, but the preexisting vascular disease burden warrants equal scrutiny.

Female Sexual Dysfunction on Lisinopril

Female sexual dysfunction (FSD) on antihypertensives is dramatically understudied. Most available data come from trials that enrolled predominantly male participants or used male-specific endpoints like erections and ejaculation. This is a real gap in the evidence base.

What Limited Data Show

A 2006 cross-sectional survey published in the Journal of Sexual Medicine evaluated 417 women on antihypertensive therapy. Women on diuretics and beta-blockers reported the highest rates of decreased lubrication, reduced desire, and difficulty reaching orgasm. Women on ACE inhibitors reported rates comparable to calcium channel blocker users. ACE inhibitor users had adjusted odds of sexual dysfunction approximately 40% lower than diuretic users in that cohort.

Bradykinin and Female Genital Vasodilation

The same NO-dependent pathway relevant to male erections also drives female genital vasocongestion. Bradykinin accumulation from ACE inhibition may preserve clitoral and vaginal blood flow, though no lisinopril-specific trial has evaluated this endpoint. The Female Sexual Function Index (FSFI) has not been used as a primary or secondary outcome in any ACE inhibitor randomized controlled trial as of January 2025.

Practical Guidance for Clinicians

Ask female patients directly. The American Heart Association's 2018 scientific statement on sexual function and cardiovascular disease recommends that clinicians routinely screen for sexual dysfunction in patients on antihypertensives using validated questionnaires, noting that "sexual concerns are frequently underreported by patients and underasked by providers." Women reporting FSD on lisinopril should be offered structured assessment before attributing the symptom to the drug.

Cough, Quality of Life, and the Indirect Sexual Health Connection

ACE inhibitor-induced cough occurs in 10 to 15% of Caucasian patients and up to 35 to 40% of Asian patients. The incidence in a large UK cohort (N=7,512) was 12.3% for lisinopril specifically. This matters for sexual health indirectly: cough disrupts sleep, reduces physical stamina, and significantly lowers quality of life scores. Any of those downstream effects can suppress libido regardless of direct drug action on the reproductive axis.

When Cough Mimics a Sexual Complaint

Patients sometimes misattribute fatigue and reduced sexual desire to the antihypertensive itself when the actual culprit is cough-disrupted sleep. Switching to an ARB (losartan, valsartan, olmesartan) eliminates cough completely in >98% of cases and, as noted above, may carry a slight advantage for male erectile function through AT1 blockade. A 2003 Cochrane review confirmed that ARBs produce significantly less cough than ACE inhibitors with comparable blood pressure reduction.

Comparing Drug Classes: A Clinical Framework for Sexual Function

When a patient's sexual function is a high-priority concern, drug class selection should be deliberate. The hierarchy below synthesizes TOMHS, LIFE subgroup data, the ALLHAT spontaneous reports, and the 2018 AHA sexual health statement.

Tier 1: Best-Tolerated Classes

Calcium channel blockers (amlodipine, nifedipine): No bradykinin effect, no direct adrenergic inhibition, neutral to mildly favorable sexual function profile. TOMHS enalapril and amlodipine both outperformed chlorthalidone and acebutolol.

ARBs (losartan, valsartan): Losartan has the only randomized subgroup evidence showing an improvement in sexual function versus an active comparator. The LIFE subgroup showed a statistically significant improvement in sexual activity score (P<0.05) for losartan versus atenolol. This ARB advantage may stem from uricosuric effects of losartan reducing gout-related fatigue in addition to AT1 blockade.

Tier 2: Acceptable Tolerance

ACE inhibitors (lisinopril, enalapril, ramipril): Lower sexual dysfunction risk than beta-blockers and thiazides. Bradykinin accumulation theoretically preserves NO signaling. Cough affects 10 to 15% of users and can indirectly reduce libido and energy.

Tier 3: Higher Sexual Dysfunction Risk

Beta-blockers (atenolol, metoprolol): Atenolol produced a 17% ED rate at 4 years in TOMHS vs. Placebo's 13%. Mechanism involves reduced pelvic blood flow via decreased cardiac output and possible central serotonergic effects. Vasodilatory beta-blockers like carvedilol and nebivolol have better profiles. Nebivolol's NO-releasing mechanism produces significantly lower ED rates than atenolol in comparative trials.

Thiazide diuretics (chlorthalidone, hydrochlorothiazide): TOMHS showed 20% ED at 48 months with chlorthalidone. Hypovolemia and zinc depletion are proposed mechanisms. Spironolactone carries additional risk through androgen receptor antagonism.

Managing Sexual Dysfunction in Patients Already on Lisinopril

Not every patient reporting sexual dysfunction on lisinopril needs a drug switch. A structured approach reduces unnecessary medication changes while addressing a quality-of-life concern that many patients consider as important as blood pressure control itself.

Step 1: Confirm Blood Pressure Is Actually Controlled

Uncontrolled hypertension worsens ED more than most antihypertensives do. A target systolic blood pressure below 130 mmHg, per the 2017 ACC/AHA hypertension guideline, is associated with improved endothelial function over 12 to 24 months. Check the home blood pressure log before changing medications.

Step 2: Evaluate Concurrent Medications

Beta-blockers, alpha-agonists (clonidine), thiazides, spironolactone, and multiple psychotropic drug classes each worsen sexual function. Polypharmacy is a common confounder. SSRIs alone cause sexual dysfunction in 30 to 40% of users according to a 2016 systematic review (N=6,297).

Step 3: Assess Hormonal Status

Free testosterone below the normal range explains more ED in middle-aged hypertensive men than any antihypertensive drug. Order a morning total and free testosterone, SHBG, and LH before attributing the complaint to lisinopril. The Endocrine Society guideline defines biochemical hypogonadism as a morning total testosterone consistently below 300 ng/dL. Hypogonadism and cardiovascular disease share overlapping risk factors and frequently coexist.

Step 4: Consider a Supervised Drug Switch

If Steps 1 to 3 fail to identify another cause, a supervised switch from lisinopril to losartan 50 mg daily is reasonable. Blood pressure should be reassessed at 4 and 8 weeks to confirm equivalence. Sexual function should be reassessed using the IIEF-5 (men) or FSFI (women) at 12 weeks. The IIEF-5 has a minimal clinically important difference of 5 points.

Step 5: PDE5 Inhibitors Are Safe With Lisinopril

Sildenafil, tadalafil, and vardenafil are not contraindicated with ACE inhibitors. The primary safety concern for PDE5 inhibitors is co-administration with nitrates, not ACE inhibitors. A pharmacokinetic interaction study found no clinically significant additive hypotension between lisinopril 10 to 20 mg and sildenafil 50 to 100 mg. Patients can be reassured on this point.

Testosterone, Lisinopril, and the Hormonal Axis

ACE inhibitors do not directly suppress gonadotropin-releasing hormone (GnRH), LH, or testosterone production through any established mechanism. A cross-sectional study of 1,822 men in the European Male Aging Study found no association between ACE inhibitor use and lower serum testosterone after multivariate adjustment for age, BMI, and comorbidities. This contrasts with beta-blockers, which have been associated in some cohorts with modestly lower free testosterone.

Hypertension itself, through chronically elevated cortisol and inflammation, may suppress testosterone over time. Treating hypertension effectively with any well-tolerated agent, including lisinopril, may therefore improve the hormonal environment even without a direct endocrine mechanism.

Practical Takeaways for Prescribers

Patients starting lisinopril for the first time should receive a brief, direct conversation about the drug's sexual function profile. Silence on this topic predicts silent non-adherence: a 2009 study published in the Journal of Clinical Hypertension found that 58% of patients who stopped antihypertensives without telling their doctor cited sexual side effects as the primary reason.

Use a validated instrument at baseline. A single IIEF-5 score before prescribing takes under two minutes and creates a documented comparison point if a complaint arises at follow-up. Tell patients that lisinopril's sexual function track record is better than most alternatives, but that their individual experience matters and is worth reporting.

If cough develops and quality of life deteriorates, switch promptly. Preserving adherence to antihypertensive therapy is more cardiovascularly important than staying within a specific drug class. A patient who stops lisinopril due to cough-related misery and goes untreated is in a far worse position than one who takes losartan comfortably for 20 years.

For men with both hypertension and erectile dysfunction who require pharmacologic treatment for ED, tadalafil 5 mg daily as a PDE5 inhibitor has a 2023 evidence base supporting its use alongside ACE inhibitors without meaningful hemodynamic interaction. Start at the lower dose and titrate based on response.